3/30
08:13 am
vnrx
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
Medium
Report
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
3/26
08:17 am
vnrx
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
Medium
Report
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
3/25
04:12 pm
vnrx
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
Low
Report
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
3/25
08:17 am
vnrx
Volition Announces Detection of Over 95% of Early-Stage Cancers
High
Report
Volition Announces Detection of Over 95% of Early-Stage Cancers
3/18
08:31 am
vnrx
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA [Yahoo! Finance]
High
Report
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA [Yahoo! Finance]
3/18
08:17 am
vnrx
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Low
Report
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
3/6
08:10 am
vnrx
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
Medium
Report
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
2/25
08:39 am
vnrx
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
High
Report
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
2/25
08:10 am
vnrx
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
High
Report
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
2/10
08:07 am
vnrx
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
High
Report
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
2/9
05:20 pm
vnrx
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Low
Report
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
2/4
08:45 am
vnrx
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
Low
Report
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
1/30
08:50 am
vnrx
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
Medium
Report
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
1/27
08:00 am
vnrx
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Low
Report
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
1/21
08:00 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
High
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
1/20
08:25 am
vnrx
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Low
Report
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
1/16
08:45 am
vnrx
Volition Sponsors Symposium at Veterinary Meeting and Expo
Medium
Report
Volition Sponsors Symposium at Veterinary Meeting and Expo
1/9
08:02 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
1/8
09:23 am
vnrx
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]
Low
Report
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]
1/8
09:15 am
vnrx
VolitionRx Secures $2.0 Million in Funding
Medium
Report
VolitionRx Secures $2.0 Million in Funding
1/8
08:45 am
vnrx
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Medium
Report
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats